13-Mar-2026
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN (minocycline HCl) Microspheres
PRNewswire (Thu, 19-Feb 8:00 AM ET)
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
PRNewswire (Wed, 11-Feb 8:00 AM ET)
Market Chameleon (Fri, 23-Jan 3:09 AM ET)
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
PRNewswire (Fri, 23-Jan 7:45 AM ET)
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
PRNewswire (Wed, 21-Jan 7:00 AM ET)
Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Mon, 5-Jan 7:00 AM ET)
Bausch Health Announces Final Results and Expiration of Exchange Offers
ACCESS Newswire (Tue, 23-Dec 5:35 PM ET)
Market Chameleon (Mon, 1-Dec 3:41 AM ET)
Market Chameleon (Thu, 30-Oct 7:30 AM ET)
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Bausch Health Companies trades on the NYSE stock market under the symbol BHC.
As of March 13, 2026, BHC stock price declined to $4.96 with 1,921,331 million shares trading.
BHC has a beta of 1.28, meaning it tends to be more sensitive to market movements. BHC has a correlation of 0.10 to the broad based SPY ETF.
BHC has a market cap of $1.84 billion. This is considered a Small Cap stock.
Last quarter Bausch Health Companies reported $3 billion in Revenue and $1.10 earnings per share. This beat revenue expectation by $91 million and missed earnings estimates by -$.14.
In the last 3 years, BHC traded as high as $11.46 and as low as $3.96.
The top ETF exchange traded funds that BHC belongs to (by Net Assets): DFIS, DISV, PPH, DFIC, DFAX.
BHC has underperformed the market in the last year with a price return of -28.0% while the SPY ETF gained +21.4%. BHC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -28.3% and -16.4%, respectively, while the SPY returned -2.6% and -3.5%, respectively.
BHC support price is $4.88 and resistance is $5.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHC shares will trade within this expected range on the day.